These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31473344)

  • 1. Effect of Treatment Modalities on Progression-Free Survival and Overall Survival in Molecularly Subtyped World Health Organization Grade II Diffuse Gliomas: A Systematic Review.
    Ghaffari-Rafi A; Samandouras G
    World Neurosurg; 2020 Jan; 133():366-380.e2. PubMed ID: 31473344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Temozolomide Regimen on Survival Outcomes in Molecularly Stratified WHO Grade II Gliomas: A Systematic Review.
    Ghaffari-Rafi A; Ghaffari-Rafi S; Leon-Rojas J
    Asian J Neurosurg; 2021; 16(1):14-23. PubMed ID: 34211862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas.
    Sagberg LM; Salvesen Ø; Jakola AS; Thurin E; De Dios E; Nawabi NLA; Kilgallon JL; Bernstock JD; Kavouridis VK; Smith TR; Solheim O
    Acta Oncol; 2024 Oct; 63():798-804. PubMed ID: 39428639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in presentation, treatment, and outcomes of adult low-grade gliomas over the past fifty years.
    Youland RS; Schomas DA; Brown PD; Nwachukwu C; Buckner JC; Giannini C; Parney IF; Laack NN
    Neuro Oncol; 2013 Aug; 15(8):1102-10. PubMed ID: 23814262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study.
    Koo T; Lim DH; Seol HJ; Dho YS; Kim IH; Chang JH; Lee J; Jung TY; Gwak HS; Cho KH; Hong CK; Lee IJ; Kim E; Kim JH; Hong YK; Jang HS; Kim CY; Kim IA; Kim SH; Kim YI; Kim EY; Kim WC; Hong S
    J Neurooncol; 2018 Nov; 140(2):445-455. PubMed ID: 30097825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
    Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.
    Ho CY; Mobley BC; Gordish-Dressman H; VandenBussche CJ; Mason GE; Bornhorst M; Esbenshade AJ; Tehrani M; Orr BA; LaFrance DR; Devaney JM; Meltzer BW; Hofherr SE; Burger PC; Packer RJ; Rodriguez FJ
    Acta Neuropathol; 2015 Oct; 130(4):575-85. PubMed ID: 26264609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current knowledge and treatment strategies for grade II gliomas.
    Narita Y
    Neurol Med Chir (Tokyo); 2013; 53(7):429-37. PubMed ID: 23883553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
    Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
    Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection.
    Nitta M; Muragaki Y; Maruyama T; Ikuta S; Komori T; Maebayashi K; Iseki H; Tamura M; Saito T; Okamoto S; Chernov M; Hayashi M; Okada Y
    Neurosurg Focus; 2015 Jan; 38(1):E7. PubMed ID: 25599276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of surgery in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
    Aghi MK; Nahed BV; Sloan AE; Ryken TC; Kalkanis SN; Olson JJ
    J Neurooncol; 2015 Dec; 125(3):503-30. PubMed ID: 26530265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
    Zhou H; Vallières M; Bai HX; Su C; Tang H; Oldridge D; Zhang Z; Xiao B; Liao W; Tao Y; Zhou J; Zhang P; Yang L
    Neuro Oncol; 2017 Jun; 19(6):862-870. PubMed ID: 28339588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of DNA ploidy with intraoperative flow cytometry may predict long-term survival of patients with supratentorial low-grade gliomas: Analysis of 102 cases.
    Suzuki A; Maruyama T; Nitta M; Komori T; Ikuta S; Chernov M; Tamura M; Kawamata T; Muragaki Y
    Clin Neurol Neurosurg; 2018 May; 168():46-53. PubMed ID: 29522936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
    Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
    Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
    Wahl M; Phillips JJ; Molinaro AM; Lin Y; Perry A; Haas-Kogan DA; Costello JF; Dayal M; Butowski N; Clarke JL; Prados M; Nelson S; Berger MS; Chang SM
    Neuro Oncol; 2017 Feb; 19(2):242-251. PubMed ID: 27571885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
    Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
    Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016.
    Compes P; Tabouret E; Etcheverry A; Colin C; Appay R; Cordier N; Mosser J; Chinot O; Delingette H; Girard N; Dufour H; Metellus P; Figarella-Branger D
    J Neurooncol; 2019 May; 142(3):511-520. PubMed ID: 30756272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.
    Cimino PJ; Zager M; McFerrin L; Wirsching HG; Bolouri H; Hentschel B; von Deimling A; Jones D; Reifenberger G; Weller M; Holland EC
    Acta Neuropathol Commun; 2017 May; 5(1):39. PubMed ID: 28532485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insular glioma resection: assessment of patient morbidity, survival, and tumor progression.
    Sanai N; Polley MY; Berger MS
    J Neurosurg; 2010 Jan; 112(1):1-9. PubMed ID: 19612970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.
    Rogers TW; Toor G; Drummond K; Love C; Field K; Asher R; Tsui A; Buckland M; Gonzales M
    J Neurooncol; 2018 Mar; 137(1):181-189. PubMed ID: 29218432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.